Moderna (NASDAQ:MRNA) Sets New 1-Year Low - Time to Sell?

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $23.76 and last traded at $24.08, with a volume of 16041074 shares changing hands. The stock had previously closed at $25.73.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MRNA. Royal Bank of Canada reiterated a "sector perform" rating and set a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. UBS Group reduced their target price on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and lowered their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Berenberg Bank boosted their price objective on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a report on Thursday, January 16th. Finally, Morgan Stanley lowered their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Moderna has a consensus rating of "Hold" and a consensus price target of $58.70.

Moderna Stock Up 6.9 %

The company has a 50 day simple moving average of $31.56 and a 200 day simple moving average of $41.01. The stock has a market cap of $10.13 billion, a price-to-earnings ratio of -2.82 and a beta of 2.23.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Sentry Investment Management LLC acquired a new position in Moderna in the 1st quarter worth about $31,000. Wilmington Savings Fund Society FSB increased its stake in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc bought a new position in Moderna in the 4th quarter valued at approximately $37,000. Venturi Wealth Management LLC boosted its position in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares during the period. Finally, Crowley Wealth Management Inc. bought a new stake in Moderna during the 4th quarter worth approximately $41,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.